Icotrokinra

Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease[1].

Product Specifications

CAS Number

[2763602-16-8]

Product Name Alternative

JNJ-77242113; JNJ-2113; PN-235

UNSPSC

12352209

Target

IFNAR; Interleukin Related; STAT

Type

Peptides

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/icotrokinra.html

Purity

99.9

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

NCCOC(C=C1)=CC=C1C[C@H](NC([C@H]2NC([C@@H](NC([C@@H](NC([C@](NC([C@@H](NC([C@H](C(C)(SSC2(C)C)C)NC(C)=O)=O)CC(N)=O)=O)([H])[C@H](O)C)=O)CC(C3=CC=C4)=CNC3=C4C)=O)CCCCNC(C)=O)=O)=O)C(N[C@@H](CC5=CC6=C(C=CC=C6)C=C5)C(NC7(CCOCC7)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(N(C)CC(N)=O)=O)CC8=CN=CC=C8)=O)=O)=O)=O)=O

Molecular Formula

C90H120N20O22S2

Molecular Weight

1898.17

References & Citations

[1]Fourie AM, et al., JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Sci Rep. 2024 Jul 30;14 (1) :17515.